Kangmei Pharmaceutical announced the reorganization!

01 Reorganization

On September 11, Kangmei Pharmaceutical Co.

The announcement stated that Kangmei Pharmaceutical's reorganization progressed this month to receive the "Decision Letter" of Jieyang Intermediate People's Court, which recognized the composition of the company's creditors committee

Kangmei Pharmaceutical was ruled by the Jieyang City Intermediate People's Court to accept the reorganization, and there is a risk of being declared bankrupt due to the failure of the reorganization

Kangmei Pharmaceuticals stated that if the company implements the reorganization and completes the execution, it will help improve the company’s asset-liability structure and increase the company’s profitability.

On April 23, Kangmei Pharmaceutical issued the third risk warning announcement regarding the possible delisting risk warning of the company's stock

Along with the delisting risk announcement, there is also the "Announcement on Creditors' Application to the Court for Bankruptcy and Reorganization of the Company".

The announcement pointed out that if the court formally accepts the application for reorganization of the company, the company will be at risk of being declared bankrupt due to the failure of the reorganization

It is worth noting that on April 20, April 22, and April 23, Kangmei Pharmaceutical issued three intensive releases of company stocks that may be subject to delisting risk warnings

Public information shows that Kangmei Pharmaceutical was established in 1997 and was once a leading company in the pharmaceutical industry.

02 Dilemma

On September 2, 2020, ST Kangmei issued an announcement that the company's controlling shareholder will be changed to Yilin Investment, and the company has no actual controller

Yilin Investment was established in August 2020, and took over Kangmei Pharmaceutical within a month after its establishment.

Cyberlane's search data in Tianyan found that there are three shareholders of Yilin Investment, namely Jieyang City Investment and Construction Group, Guangdong Jinfu Equity Custody Center, and Guangzhou Shennong Traditional Chinese Medicine Development Co.

Jieyang City Investment and Construction Group has two shareholders, namely China Development Bank and Jieyang SASAC; Guangdong Jinfu Equity Custody Center is 100% controlled by Guangdong SASAC; Guangzhou Shennong’s Traditional Chinese Medicine Development Co.

Kangmei Pharmaceutical said that the purpose of this trusteeship is to help the company bail out and maintain the company's production and operation stability

From a long-term perspective, from 2015 to 2017, Kangmei Pharmaceutical achieved revenue of 18.

Kangmei Pharmaceutical, which has achieved high performance all the way, was pressed the pause button due to the mysterious disappearance of the company's nearly 30 billion yuan of funds

The investor protection agency fully responded to market calls, accepted the entrustment of investors in accordance with the law, and participated in Kangmei Pharmaceutical's representative litigation as a representative
.

The China Securities Regulatory Commission supports this and will supervise the participation of investor protection agencies in litigation work in accordance with the law to effectively protect the legitimate rights and interests of investors
.

The 2021 semi-annual report of Kangmei Pharmaceutical shows that its revenue reached 2.
069 billion yuan, a year-on-year decline of 17.
78%
.
In the 2020 performance report, Kangmei Pharmaceutical achieved revenue of 5.
412 billion yuan, a year-on-year decrease of 52.
72%
.

03 Focus

There are opinions in the industry that Kangmei Pharmaceutical is the first step to solve the debt problem, and the development of its business segments is whether it can turn back losses in the future and is the key to achieving sustainable development
.

Kangmei Pharmaceutical stated in its performance report for the first half of 2021 that the company continued to implement the development strategy of focusing on the main business, focusing on the main business of traditional Chinese medicine decoction pieces, and continuously optimizing the business structure
.

Chinese herbal medicine is one of the most competitive business segments of Kangmei Pharmaceutical
.
Kangmei Pharmaceuticals stated that it has completely built an integrated business system of the Chinese medicine industry chain, formed a mastery of the core resources of the supply of Chinese medicinal materials in the upstream, and also built a modern pharmaceutical logistics system and a collection of medical institution resources, smart pharmacies, and pharmacies in the downstream.
An all-round multi-level marketing network integrating OTC retail, chain pharmacies, direct sales, medical e-commerce, and mobile medical
.
These will be conducive to taking advantage of the channel in a relatively short period of time to form the digestion of new production capacity, thereby rapidly expanding the scale of Chinese herbal medicine decoction pieces business and increasing market share
.

Shen Yong, chairman of Beijing Shengshikanglai Traditional Chinese Medicine Marketing Planning Company, said to Saibolan that Kangmei Pharmaceutical has its unique advantages and should use its accumulated experience over the years to develop its advantages
.

In recent years, many traditional Chinese medicine companies have been actively transforming and upgrading to PD-1 and biological drugs.
Cosmetics and skin care products are also choices for many pharmaceutical companies to further develop
.

The 2020 version of the pharmacopoeia opinion draft has proposed to add pesticide residues and heavy metal inspection items to 544 medicinal materials
.
From the point of view of procurement by manufacturers, not only will the inspection cost increase, but the living environment will also become more difficult
.
If a relevant indicator does not meet the standard, the company may be eliminated by the market
.

According to statistics from the Health Times, as of September 2, more than 70 listed Chinese medicine companies have released their 2021 semi-annual reports.
Most Chinese medicine companies still account for a relatively low proportion of R&D in revenue, and most do not exceed 5%
.

In the context of the continuous strengthening of pharmaceutical supervision, the transformation of traditional Chinese medicine companies is imminent, and product safety cannot be ignored.
Focusing on research and development is an important step in the development of pharmaceutical companies
.

The above-mentioned people further stated that the frequent reforms of Chinese medicine policies have caused some pharmaceutical companies to lack guidance on policies in the past
.
Under the background of various national policy reforms, the problems of enterprises have been exposed and irregularities have appeared.
In fact, they are not the Kangmei family
.
Relevant companies must always pay attention to market changes, and the importance of policies to the Chinese medicine industry is self-evident
.

"Relevant news has been reported on the centralized procurement of Chinese medicine.
While pharmaceutical companies are paying attention to the centralized procurement of proprietary Chinese medicines, they must also make corresponding changes in their promotion and development models
.
"

Kangmei Pharmaceutical was once a white horse stock that was favored by everyone in the industry.
Its market value reached more than 130 billion at its peak.
Now it has been implemented many times of stock risk warnings and has entered the restructuring stage.
What will ST Kangmei look like in the future is still worthy of attention
.